OvartiX LtD
Drug Discovery
- [email protected]
- Phone
- +447437331141
- Website
- https://ovartix.com/
- Membership category
- Corporate Introductory
OvartiX LtD, 59 Weymouth Street, London, W1G 8NT, United Kingdom
OvartiX LtD at a glance
About OvartiX LtD
OvartiX is a women's health drug discovery company pioneering novel therapeutics for female reproductive disorders. Their multi-faceted drug discovery platform integrates large-scale human multi-omics data, ovarian 2D and 3D cell-engineered models to unlock drug discovery opportunities for previously inaccessible targets rooted in ovarian dysfunction and ageing. OvartiX platform has broad applicability across a number of ovarian conditions, with the priorities being infertility, PCOS and ovarian preservation. Besides the platform that serves as an innovation engine, OvartiX is developing a specific non-hormonal therapeutic asset that focuses on two indications:
1. Augmenting IVF and egg freezing by increasing egg yield without the exposure to high levels of hormonal stimuli, enhancing the likelihood of a successful pregnancy in a single cycle
2. Preserving ovarian reserve and endocrine function during cancer treatment in reproductively active women
The company is backed by the BioInnovation Institute (Novo Nordisk Foundation), Accelerate@Babraham and Microsoft for Startups, and led by world renewed experts in reproductive medicine, Prof Eva Hoffmann, Dr Stasa Stankovic, Prof Anna Murray and Prof John Perry.
The founders are recognised as world leaders in women's health with a track record of more than 20 years.
- Popular Media: BBC Science Focus, BBC Click, Forbes, Bloomberg, BBC Science Focus, The Guardian
- Scientific Papers: Nature, Nature, Nature Medicine, MedRxiv, Nature Genetics
